Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704571 | 0.95 | PDGFRB (1.00) | PDGFRB | |
| SCHEMBL6704365 | 0.95 | PDGFRB (1.00) | PDGFRB | |
| SCHEMBL6703374 | 0.94 | PDGFRB (1.00) | PDGFRB | |
| SCHEMBL5033009 | 0.90 | PDGFRB (0.93) | PDGFRB | |
| SCHEMBL906239 | 0.90 | PDGFRB (1.00) | PDGFRB | |
| SCHEMBL2921461 | 0.89 | PDGFRB (1.00) | PDGFRB | |
| SCHEMBL13330488 | 0.89 | PDGFRB (0.93) | PDGFRB | |
| SCHEMBL3314156 | 0.89 | PDGFRB (1.00) | PDGFRB | |
| SCHEMBL5033322 | 0.88 | PDGFRB (1.00) | PDGFRB | |
| SCHEMBL13330477 | 0.88 | PDGFRB (0.93) | PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315715-B1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1315715-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2003-06-04 | — | — | EP | claimed |
| WO-2002016351-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1964839-A2 | Quinazoline derivatives as kinase inhibitors | Millennium Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964839-A2 | Quinazoline derivatives as kinase inhibitors | Millennium Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1315715-B1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1315715-B1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-07-23 | — | — | EP | disclosed |
| US-6982266-B2 | N-(4-indol-5-yloxyphenyl){4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}carboxamide for example; antiproliferative agents which inhibit phosphorylation of kinases such as tyrosine kinase; cancer, arteriosclerosis | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050288297-A1 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-20050101609-A1 | Quinazoline derivatives as kinase inhibitors | KYOWA HAKKO KOGYO CO, LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1315715-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002016351-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDGFRB 10/4885 |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDGFRB 10/4885 |
| US-20050101609-A1 | Quinazoline derivatives as kinase inhibitors | TNNI3K, PDGFRA, TEK | PDGFRB 4/4885 |
| US-20050288297-A1 | Quinazoline derivatives as kinase inhibitors | WNK2, WNK1, WNK3 | PDGFRB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.